Advent announces merger of Cohance with Suven

Private equity major, Advent in December 2022 had taken a majority control in Suven Pharmaceuticals (SP). At that time, Advent had disclosed in the filings that it intends to explore the merger of it’s umbrella CDMO entity, Cohance Lifesciences into SP and hence create an integrated, larger and listed franchise with the associated benefits. Now, … Read more

Polyphenols: Researchers find potential treatment route for Alzheimer’s

Scientists have found that highly abundant naturally occurring plant-based polyphenols or PPs (type of compounds) — like tannic acid found in twigs of trees like Chestnut and Oak — can help create cost-effective strategy for combating Alzheimer’s disease (AD) and reduce the societal burden of this debilitating neurodegenerative disorder. The findings are part of a … Read more

We want assurance of quality of generic medicines, says IMA President

Indian Medical Association (IMA) president Dr Sharad Agarwal has raised concerns over the quality of generic medicine made in India. In an interview, he also raised concerns on restrictions placed on doctors attending medical conferences, saying educational conferences are only a discussion forum about advancements in medicine. His remarks come amid a controversy on a … Read more

Inside COVID-19 vaccine stocks: Hope vs hype (NYSE:PFE)

With the pandemic in the rearview mirror, Wall Street has mixed views on the prospects of COVID-19 vaccine makers, as the group, once the favorite among investors, is grappling with a steep decline in sales amid falling infections. The FDA-Authorized COVID-19 makers in the U.S., Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX), Moderna (NASDAQ:MRNA), and Novavax (NASDAQ:NVAX), have … Read more

IPCA acquires significant stake in Unichem

IPCA Laboratories is acquiring 33.38% from the promoters of Unichem Laboratories (UL). Promoters before this transaction owned 50.94% of UL. Out of the balance, 9.85% was held by the institutions and 39.21% by the retail investors.  Transaction is announced @ Rs 440/ share aggregating to Rs 1,034.06 cr. This implies a premium of about 17% … Read more

Sanofi to demerge consumer healthcare business

As per newspaper reports, Sanofi India is working on spinning off it’s consumer healthcare business in India in a separate listed entity. The subject unit’s products include leading anti-allergy brands such as Allegra and Avil, pain management drug Combiflam and Vitamin D brand Depura. The business posted revenue of Rs 1,000-1,250 crore in CY22 (against … Read more

Ajanta in keeping with the tradition announces one more buyback

Ajanta Pharma has announced buyback once more. This is 4th year in a row, previous 3 details can be checked here. Current buyback details are – 22,10,500 shares constituting 1.73% of the outstanding capital Buyback price is Rs 1,425/ share which is at 17% premium to the current market price Rs 315 cr will be … Read more